+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Cholangiocarcinoma Pipeline Analysis Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102836
Cholangiocarcinoma (CCA) is a rare and aggressive cancer originating in the bile ducts, which transport bile from the liver to the digestive system. It is classified into intrahepatic, perihilar, and distal types based on its location. Symptoms often include jaundice, abdominal pain, fatigue, and unexplained weight loss. Risk factors include chronic biliary inflammation, primary sclerosing cholangitis, liver fluke infections, and exposure to toxins. Cholangiocarcinoma is typically diagnosed late due to its subtle early symptoms, making prognosis challenging. Cholangiocarcinoma pipeline analysis by the publisher highlights promising drug candidates, including small molecules, gene therapies, and monoclonal antibodies.

Report Coverage

The Cholangiocarcinoma Pipeline Analysis Report by the publisher gives comprehensive insights into cholangiocarcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cholangiocarcinoma. The cholangiocarcinoma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The cholangiocarcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with cholangiocarcinoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cholangiocarcinoma.

Cholangiocarcinoma Pipeline Outlook

Chronic inflammation and cholestasis, frequently brought on by diseases like primary sclerosing cholangitis or liver fluke infections, cause biliary epithelial cells to malignantly convert into cholangiocarcinoma. Prolonged inflammation promotes unregulated proliferation and survival by causing DNA damage, epigenetic modifications, and deregulation of carcinogenic pathways such EGFR/ERB-B2 and IL-6/STAT3. Carcinogenesis is further fueled by genetic alterations (KRAS, IDH1/2, TP53), but autocrine/paracrine signaling is maintained by cytokines and growth hormones (e.g., hepatocyte growth factor). Desmoplastic stroma and cancer-associated fibroblasts are characteristics of the tumor microenvironment that promote invasion and metastasis. Adenocarcinomas with aggressive local infiltration account for most cases (>90%).

Surgery for isolated tumors is the main treatment for cholangiocarcinoma, with the goal of removing as much cancer as possible. Chemotherapy is the mainstay of palliative care for cases that cannot be cured. The first-line treatment is cisplatin plus gemcitabine, which has been demonstrated to increase overall survival when compared to gemcitabine alone. Additionally, targeted medicines that target genetic abnormalities within cancers are becoming more popular. Clinical trials are still investigating novel approaches to improve the treatment of this difficult cancer type.

Cholangiocarcinoma Epidemiology

The prevalence of cholangiocarcinoma (CCA), which currently makes up 15% of primary liver tumors and roughly 3% of gastrointestinal cancers, is rising worldwide. Although incidence rates differ greatly by area, about 8,000 new cases are detected in the US each year. In Hong Kong, for example, the rate of intrahepatic cholangiocarcinoma (ICC) is 2.3 per 100,000, while in Argentina it is 0.14 per 100,000. All things considered, improved diagnostic procedures and a greater awareness of risk factors are responsible for the rising trends in ICC and extrahepatic cholangiocarcinoma (ECC).

Cholangiocarcinoma Pipeline Therapeutic Assessment

This section of the report covers the analysis of cholangiocarcinoma drug candidates based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecule
  • Peptide
  • Polymer
  • Monoclonal Antibody
  • Gene Therapy
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

Cholangiocarcinoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total clinical trials, with a substantial number of cholangiocarcinoma drugs undergoing clinical development.

Cholangiocarcinoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under cholangiocarcinoma pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The cholangiocarcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cholangiocarcinoma.

Cholangiocarcinoma Clinical Trials - Key Players

The report for the cholangiocarcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cholangiocarcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cholangiocarcinoma clinical trials:
  • Eli Lilly and Company
  • Incyte Corporation
  • Seagen
  • Elevar Therapeutics
  • Compass Therapeutics
  • TCR2 Therapeutics
  • Elicio Therapeutics
  • Eisai Co., Ltd.
  • Servier
  • TriSalus Life Sciences, Inc.

Cholangiocarcinoma Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cholangiocarcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cholangiocarcinoma drug candidates.

Drug: LY3410738

LY3410738 is an investigational, oral, covalent inhibitor targeting mutant isocitrate dehydrogenase (IDH) 1 and 2 enzymes, developed by Eli Lilly and Company. It is designed to bind irreversibly to mutant IDH1, blocking the production of the oncometabolite (R)-2-hydroxyglutarate ((R)-2HG), which is implicated in various cancers. LY3410738 is currently in Phase 1 of clinical trials to evaluate its safety, tolerability, and efficacy in patients with advanced solid tumors and hematologic malignancies harboring IDH1 or IDH2 mutations.

Drug: Pemigatinib

Pemigatinib, is a selective fibroblast growth factor receptor (FGFR) inhibitor developed by Incyte Corporation. It received accelerated FDA approval in 2020 for treating adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. The approval was based on the FIGHT-202 Phase 2 study, which demonstrated an overall response rate of 35.5% in patients with FGFR2 fusions. Pemigatinib is currently in Phase 3 clinical trials to further evaluate its safety and efficacy in treating cholangiocarcinoma and other FGFR-related malignancies.

Reasons To Buy This Report

The Cholangiocarcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cholangiocarcinoma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the cholangiocarcinoma pipeline insights.

Key Questions Answered in the Cholangiocarcinoma Pipeline Insight Report

  • What is the current landscape of cholangiocarcinoma pipeline drugs?
  • Which companies/institutions are developing cholangiocarcinoma emerging drugs?
  • How many phase II drugs are currently present in cholangiocarcinoma pipeline drugs?
  • Which company is leading the cholangiocarcinoma pipeline development activities?
  • What is the current cholangiocarcinoma therapeutic assessment?
  • What are the opportunities and challenges present in the cholangiocarcinoma drug pipeline landscape?
  • What is the efficacy and safety profile of cholangiocarcinoma pipeline drugs?
  • Which companies/institutions are involved in cholangiocarcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in cholangiocarcinoma?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Cholangiocarcinoma
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Cholangiocarcinoma
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Cholangiocarcinoma
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cholangiocarcinoma: Epidemiology Snapshot
5.1 Cholangiocarcinoma Incidence by Key Markets
5.2 Cholangiocarcinoma - Patients Seeking Treatment in Key Markets
6 Cholangiocarcinoma: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Cholangiocarcinoma: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Cholangiocarcinoma, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Cholangiocarcinoma Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Cholangiocarcinoma Drug Pipeline - Mid-Stage Products (Phase III & IV) (Top Drugs)
10.1 Comparative Analysis for Mid-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Pemigatinib
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Pembrolizumab
10.2.3 Other Drugs
11 Cholangiocarcinoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: LY3410738
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: CTX-009
11.2.3 Other Drugs
12 Cholangiocarcinoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: RLY-4008
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: Gavocabtagene autoleucel
12.2.3 Other Drugs
13 Cholangiocarcinoma, Key Drug Pipeline Companies
13.1 Eli Lilly and Company
13.1.1 Company Snapshot
13.1.2 Pipeline Product Portfolio
13.1.3 Financial Analysis
13.1.4 Recent News and Developments
13.2 Incyte Corporation
13.2.1 Company Snapshot
13.2.2 Pipeline Product Portfolio
13.2.3 Financial Analysis
13.2.4 Recent News and Developments
13.3 Seagen
13.3.1 Company Snapshot
13.3.2 Pipeline Product Portfolio
13.3.3 Financial Analysis
13.3.4 Recent News and Developments
13.4 Elevar Therapeutics
13.4.1 Company Snapshot
13.4.2 Pipeline Product Portfolio
13.4.3 Financial Analysis
13.4.4 Recent News and Developments
13.5 Compass Therapeutics
13.5.1 Company Snapshot
13.5.2 Pipeline Product Portfolio
13.5.3 Financial Analysis
13.5.4 Recent News and Developments
13.6 TCR2 Therapeutics
13.6.1 Company Snapshot
13.6.2 Pipeline Product Portfolio
13.6.3 Financial Analysis
13.6.4 Recent News and Developments
13.7 Elicio Therapeutics
13.7.1 Company Snapshot
13.7.2 Pipeline Product Portfolio
13.7.3 Financial Analysis
13.7.4 Recent News and Developments
13.8 Eisai Co., Ltd.
13.8.1 Company Snapshot
13.8.2 Pipeline Product Portfolio
13.8.3 Financial Analysis
13.8.4 Recent News and Developments
13.9 Servier
13.9.1 Company Snapshot
13.9.2 Pipeline Product Portfolio
13.9.3 Financial Analysis
13.9.4 Recent News and Developments
13.10 TriSalus Life Sciences, Inc.
13.10.1 Company Snapshot
13.10.2 Pipeline Product Portfolio
13.10.3 Financial Analysis
13.10.4 Recent News and Developments
14 Regulatory Framework for Drug Approval, By Region15 Terminated or Suspended Pipeline Products